Skip to content

Research and Development of Key Technologies for Intelligent Minimally invasive and Precise Treatment of Fractures (Project 3: Randomized Controlled Study on Robot-assisted Closed Reduction and Internal Fixation of Supracondylar Fractures of the Femur)

Research and Development of Key Technologies for Intelligent Minimally invasive and Precise Treatment of Fractures (Project 3: Randomized Controlled Study on Robot-assisted Closed Reduction and Internal Fixation of Supracondylar Fractures of the Femur)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124403
Enrollment
Unknown
Registered
2026-05-12
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

supracondylar fracture

Interventions

Sponsors

Beijing Jishuitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 to 80 years old, gender not limited. 2. Diagnosed as unilateral, acute, closed supracondylar fracture of the femur (AO/OTA 33-A); 3. No more than 21 days from injury to surgery; 4. Before the injury, the individual could walk independently (assistive devices are allowed).

Exclusion criteria

Exclusion criteria: 1. Open fractures or multiple severe traumas that require priority treatment; 2. Asymmetry of both lower extremities or previous malunion of the ipsilateral femoral shaft or previous malformations that significantly affect rotation/length assessment; 3. Unilateral fractures combined with fractures in other parts; 4. Pathological fractures (tumor/metabolic); 5. Previous complex implants on the same side or previous surgeries have a significant impact on the assessment; 6. Active infection or severe systemic internal medical contraindications (inability to tolerate anesthesia/surgery); 7. Cognitive impairment/Poor compliance/Pregnancy or lactation; 8. Those who the researcher deems unsuitable for inclusion in the group (such as those who cannot be followed up as planned); 9. Refuse randomization or refusal to enroll.

Design outcomes

Primary

MeasureTime frame
The excellent and good rate of closed reduction;

Secondary

MeasureTime frame
Fracture healing rate;EQ-5D-5L;HHS Score;

Countries

China

Contacts

Public ContactZhao Chunpeng

Beijing Jishuitan Hospital, Capital Medical University

Zcpllza2008@163.com+86 186 1001 2704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026